TheraVet launches osteosarcoma study

(CercleFinance.com) - TheraVet, a biotechnology company pioneering the treatment of osteoarticular diseases in companion animals, announces the launch of a clinical trial measuring the efficacy of cementoplasty with BIOCERA-VET® Osteosarcoma combined with stereotactic radiotherapy (SBRT) in patients with osteosarcoma.


' Canine osteosarcoma is usually treated by limb amputation to ensure local control of the tumor, and adjuvant chemotherapy to delay the onset of metastases '.

A promising alternative is percutaneous cementoplasty. This consists in the percutaneous injection of a bone cement - such as BIOCERA-VET® Osteosarcoma - at the level of the bone tumor, which provides analgesia and bone consolidation, thus preventing fractures
Pathologiques ' indicates the company.

Copyright (c) 2023 CercleFinance.com. All rights reserved.